FullHope Business Summary

FullHope Biomedical Co., Ltd. (7773.TWO) operates as a specialized biotechnology firm focused on the research, development, and commercialization of immune system-related therapies and diagnostic services. The company generates revenue through a diversified model encompassing contract research organization (CRO) services, immune cell manufacturing, and the operation of an immune cell bank, alongside the development of proprietary cell-based immunotherapies. Its primary business segments are divided into precision diagnostics—utilizing AI-driven immunoprofiling and circulating tumor cell (CTC) testing—and therapeutic development, which includes its FHCT001 and FHCT003 cancer treatments and the FHCT002 auto-immune cell therapy. Within the competitive landscape of Taiwan's biotech sector, FullHope positions itself as a vertically integrated player in the regenerative medicine market, competing directly with firms such as Caliway Biopharmaceuticals (6919.TW), Bora Pharmaceuticals (6472.TW), Lotus Pharmaceutical (1795.TW), and Pell Bio-Med Technology (6949.TW). The company’s leadership is anchored by a team of distinguished medical researchers and industry veterans. Chairman Dr. Yee Chao is a prominent oncologist and professor at National Yang Ming Chiao Tung University, bringing extensive clinical expertise from his tenure at Taipei Veterans General Hospital. President and Founder Dr. Jan-Mou Lee, a veteran immunologist, established the firm in 2012 after a career in scientific research and served as a key consultant in drafting Taiwan’s cell therapy regulations. The executive team is supported by a robust board and notable institutional backing, including the National Development Fund of Taiwan, which invested in the company in 2019 to accelerate its clinical trial pipeline. FullHope maintains strategic collaborations with premier medical institutions, including National Taiwan University Hospital, to validate its Good Tissue Practice (GTP) laboratory outputs and advance its international patent portfolio.